Inozyme Pharma Inc. (INZY)
0.99
0.03 (3.16%)
At close: Mar 27, 2025, 3:59 PM
0.98
-1.08%
After-hours: Mar 27, 2025, 07:56 PM EDT
3.16% (1D)
| Bid | 0.86 |
| Market Cap | 63.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -104.34M |
| EPS (ttm) | -1.62 |
| PE Ratio (ttm) | -0.61 |
| Forward PE | -1.01 |
| Analyst | Buy |
| Ask | 1.09 |
| Volume | 370,105 |
| Avg. Volume (20D) | 709,900 |
| Open | 0.95 |
| Previous Close | 0.96 |
| Day's Range | 0.94 - 1.01 |
| 52-Week Range | 0.91 - 7.79 |
| Beta | 1.31 |
About INZY
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for spec...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 67
Stock Exchange NASDAQ
Ticker Symbol INZY
Website https://www.inozyme.com
Analyst Forecast
According to 9 analyst ratings, the average rating for INZY stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 1421.30% from the latest price.
Stock Forecasts2 months ago
-14%
Inozyme Pharma shares are trading lower after mult...
Unlock content with
Pro Subscription
